Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helene Karcher

Showing results (1-10 of 35) with videos related to

Pageof 4
Sort By:
Plos One|June 9, 2016
Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell CarcinomaWitold Wiecek, Helene Karcher
Plos One|September 9, 2017
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinomaBilly Amzal, Shuai Fu, Jie Meng, et al.
The AAPS Journal|February 22, 2011
From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologicsJing Yu, Helene Karcher, Adam L Feire, et al.
American Journal of Ophthalmology|June 23, 2022
Anti-Vascular Endothelial Growth Factor Treatment Discontinuation and Interval in Neovascular Age-Related Macular Degeneration in the United StatesSophie J Bakri, Helene Karcher, Steffen Andersen, et al.
Ophthalmology and Therapy|November 3, 2022
The Treatment Patterns with Brolucizumab in Germany (REALIZE) Study: A Retrospective Cohort Study Based on Longitudinal Prescription DataRaffael G Liegl, Helene Karcher, Shala Chetty-Mhlanga, et al.
Biophysical Journal|January 31, 2006
A coarse-grained model for force-induced protein deformation and kineticsHelene Karcher, Seung E Lee, Mohammad R Kaazempur-Mofrad, et al.
Clinical Ophthalmology (Auckland, N.Z.)|August 16, 2023
Short-Term Treatment Outcomes of Brolucizumab in Patients with Neovascular Age-Related Macular Degeneration: A Multicentre Indian Real-World Evidence StudyDebdulal Chakraborty, Milan Thakkar, Ramesh Venkatesh, et al.
Ophthalmology and Therapy|June 22, 2023
Real-World Persistence and Treatment Interval in Patients with Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factors in the USASophie J Bakri, Marie-Noelle Delyfer, Jakob Grauslund, et al.
Allergy and Asthma Proceedings|November 3, 2023
Impact of COVID-19 measures on exacerbation rates and healthcare visits in US asthma patientsHelene Karcher, Matthias Schoenberger, Tejaswini Rayban, et al.
Contemporary Clinical Trials Communications|July 3, 2023
Testing the "RCT augmentation" methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectivenessClementine Nordon, Benoit Sanchez, Mei Zhang, et al.
Pageof 4

Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
Plos One|June 9, 2016
Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell CarcinomaWitold Wiecek, Helene Karcher
Plos One|September 9, 2017
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinomaBilly Amzal, Shuai Fu, Jie Meng, et al.
The AAPS Journal|February 22, 2011
From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologicsJing Yu, Helene Karcher, Adam L Feire, et al.
American Journal of Ophthalmology|June 23, 2022
Anti-Vascular Endothelial Growth Factor Treatment Discontinuation and Interval in Neovascular Age-Related Macular Degeneration in the United StatesSophie J Bakri, Helene Karcher, Steffen Andersen, et al.
Ophthalmology and Therapy|November 3, 2022
The Treatment Patterns with Brolucizumab in Germany (REALIZE) Study: A Retrospective Cohort Study Based on Longitudinal Prescription DataRaffael G Liegl, Helene Karcher, Shala Chetty-Mhlanga, et al.
Biophysical Journal|January 31, 2006
A coarse-grained model for force-induced protein deformation and kineticsHelene Karcher, Seung E Lee, Mohammad R Kaazempur-Mofrad, et al.
Clinical Ophthalmology (Auckland, N.Z.)|August 16, 2023
Short-Term Treatment Outcomes of Brolucizumab in Patients with Neovascular Age-Related Macular Degeneration: A Multicentre Indian Real-World Evidence StudyDebdulal Chakraborty, Milan Thakkar, Ramesh Venkatesh, et al.
Ophthalmology and Therapy|June 22, 2023
Real-World Persistence and Treatment Interval in Patients with Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factors in the USASophie J Bakri, Marie-Noelle Delyfer, Jakob Grauslund, et al.
Allergy and Asthma Proceedings|November 3, 2023
Impact of COVID-19 measures on exacerbation rates and healthcare visits in US asthma patientsHelene Karcher, Matthias Schoenberger, Tejaswini Rayban, et al.
Contemporary Clinical Trials Communications|July 3, 2023
Testing the "RCT augmentation" methodology: A trial simulation study to guide the broadening of trials eligibility criteria and inform on effectivenessClementine Nordon, Benoit Sanchez, Mei Zhang, et al.
Pageof 4